Key Findings
Preliminary data from a Phase 1 basket trial indicate that zugo-cel is well tolerated and effective across multiple refractory rheumatologic indications. As of October 15, 2026, 21 patients have been dosed. In the systemic sclerosis (SSc) cohort, 83% (5/6) of patients receiving standard lymphodepletion achieved a revised Composite Response Index in Systemic Sclerosis (rCRISS)-25 response at Month 3, with all five responders maintaining their response. Additionally, all nine patients with idiopathic inflammatory myopathy (IIM)—including those with antisynthetase syndrome, dermatomyositis, and immune-mediated necrotizing myopathy—achieved a moderate or major Total Improvement Score (TIS) response.
Technical Details
Zugo-cel is an off-the-shelf allogeneic CAR-T cell therapy targeting CD19. It utilizes CRISPR/Cas9 for targeted gene knockout and CAR insertion to enable immune evasion and enhance T effector cell potency, removing the need for HLA matching. The trial is currently evaluating dose escalation; six patients dosed at the 200 million CAR+ cell level demonstrated higher CAR-T cell expansion compared to those at the 100 million level.
Safety data across all 21 patients showed no dose-limiting toxicities, no ICANS, no IEC-HS, and no cytokine release syndrome (CRS) above Grade 2. There were no reported deaths, severe infections, or prolonged cytopenias.
Background and Context
The rheumatology basket trial focuses on systemic lupus erythematosus (SLE), SSc, and IIM. In the SLE cohort, two of three evaluable patients maintained drug-free DORIS remission through at least Month 9. Beyond rheumatology, CRISPR Therapeutics is evaluating zugo-cel in Phase 1 trials for autoimmune hematologic diseases (including ITP and wAIHA), autoimmune neurologic diseases (including progressive multiple sclerosis and various autoimmune encephalitides), and relapsed or refractory B-cell malignancies.
Significance and Outlook
The results suggest that an allogeneic, “off-the-shelf” approach may provide a meaningful treatment option for patients with refractory autoimmune diseases who typically face a lifelong burden of immunosuppressive therapy. The company continues to advance the therapy across its various autoimmune and immuno-oncology pipelines.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



